

John R Wingard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1186630/publications.pdf>

Version: 2024-02-01

492
papers

54,241
citations

4103

90
h-index

1551

223
g-index

552
all docs

552
docs citations

552
times ranked

31590
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolomic Markers of Persistent Fatigue Among Allogeneic Stem Cell Transplant Survivors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S51.	0.6	0
2	Evaluation of Distress Subscales in Relationship with Transplant Characteristics in Elderly (>=60) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 S443-S444.	0.6	0
3	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2022, 9, e374-e384.	2.2	11
4	Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 606.e1-606.e8.	0.6	3
5	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 603.e1-603.e7.	0.6	4
6	Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. <i>Cancer Medicine</i> , 2021, 10, 70-78.	1.3	26
7	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 183.e1-183.e7.	0.6	6
8	Gut Microbiota Dysbiosis Associated with Persistent Fatigue in Hematopoietic Cell Transplantation Survivors. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 498.e1-498.e8.	0.6	10
9	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	3.2	14
10	Aspergillus Polymerase Chain Reaction—An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, S95-S101.	2.9	17
11	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	0.6	13
12	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 507-516.	0.6	26
13	Prospective Evaluation of Galactomannan and (1->3)-D-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 864-871.	0.6	14
14	COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 533-539.	0.6	1
15	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab441.	0.4	3
16	Microbiota phylogenetic analysis revealed decreased abundance of <i>Faecalibacterium prausnitzii</i> , an anti-inflammatory commensal bacterium, in patients with chronic graft-versus-host disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 263-265.	0.6	3
17	Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1007.e1-1007.e8.	0.6	5
18	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	0.6	0

#	ARTICLE	IF	CITATIONS
19	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201. <i>Blood</i> , 2021, 138, 1772-1772.	0.6	1
20	Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥60 Years) Hematopoietic Cell Transplant (HCT) Patients. <i>Blood</i> , 2021, 138, 426-426.	0.6	0
21	Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors. <i>Blood</i> , 2021, 138, 4123-4123.	0.6	0
22	Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors. <i>Blood</i> , 2021, 138, 3932-3932.	0.6	0
23	Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 23-31.	0.6	9
24	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
25	Reply to Luppi et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 3266-3266.	2.9	0
26	Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2001-2010.	2.0	8
27	Galectin-3 enhances neutrophil motility and extravasation into the airways during <i>Aspergillus fumigatus</i> infection. <i>PLoS Pathogens</i> , 2020, 16, e1008741.	2.1	33
28	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
29	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 2121-2131.	1.3	7
30	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.	2.0	4
31	Global Metabolomics in Allogeneic Hematopoietic Cell Transplantation Recipients Discordant for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1803-1810.	2.0	9
32	Hematopoietic Cell Transplantation (HCT) Predictions for the Year 2023. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S201.	2.0	0
33	Absolute Lymphocyte Count Recovery Following Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S301-S302.	2.0	0
34	Development of the Renal Adjusted Hematopoietic Cell Transplant Comorbidity Index (RA-HCT-CI) Using Different Levels of Renal Dysfunction According to Estimated Glomerular Filtration Rate (eGFR). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S134-S135.	2.0	0
35	Dietary Intake and Diet Quality of Hematopoietic Stem Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1154-1159.	2.0	11
36	Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2020, 189, e211-e213.	1.2	9

#	ARTICLE	IF	CITATIONS
37	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. <i>Blood Advances</i> , 2020, 4, 706-716.	2.5	11
38	Bleeding and thrombosis outcomes in patients with acute leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, e19501-e19501.	0.8	1
39	Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2020, 136, 33-34.	0.6	0
40	Impact of Severity of Acute Graft-Versus-Host Disease on Healthcare Resource Utilization, Cost and Outcomes. <i>Blood</i> , 2020, 136, 37-38.	0.6	0
41	Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1673.	3.8	67
42	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	1.3	19
43	Prevention of Fungal Disease. , 2019, , 1111-1121.		0
44	Antimicrobial Drug Prophylaxis: Challenges and Controversies. , 2019, , 1123-1135.		0
45	Impact of Autologous Blood Transfusion after Bone Marrow Harvest on Donor Health and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S198-S199.	2.0	1
46	Peripheral Blood Stem Cell Collection in One Day Is Preferable to Two Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S199-S200.	2.0	0
47	Myeloablative vs reduced intensity T-cellâ€“replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019, 3, 2836-2844.	2.5	38
48	A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. <i>Blood Advances</i> , 2019, 3, 1837-1847.	2.5	10
49	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	2.5	13
50	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. <i>Haematologica</i> , 2019, 104, 1084-1092.	1.7	46
51	Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 562-569.	2.0	16
52	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , 2019, 68, 850-853.	2.9	31
53	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
54	Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients. <i>Medical Mycology</i> , 2019, 57, 38-44.	0.3	8

#	ARTICLE	IF	CITATIONS
55	Outcomes of autologous blood collection prior to bone marrow harvest for matched unrelated donors.. Journal of Clinical Oncology, 2019, 37, e18535-e18535.	0.8	0
56	Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors. Blood, 2019, 134, 4565-4565.	0.6	0
57	Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2019, 134, 3256-3256.	0.6	0
58	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biology of Blood and Marrow Transplantation, 2018, 24, 1322-1340.	2.0	85
59	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. Biology of Blood and Marrow Transplantation, 2018, 24, 1119-1124.	2.0	33
60	Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial. Bone Marrow Transplantation, 2018, 53, 1038-1043.	1.3	6
61	Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. Journal of Clinical Apheresis, 2018, 33, 29-37.	0.7	36
62	Lifestyle Behaviors, Perceived Stress, and Inflammation of Individuals With Chronic Graft-Versus-Host Disease. Cancer Nursing, 2018, 41, 11-22.	0.7	6
63	CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation. Leukemia Research, 2018, 74, 110-112.	0.4	6
64	Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives. Vaccine, 2018, 36, 6043-6052.	1.7	3
65	Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clinical Cancer Research, 2018, 24, 4098-4109.	3.2	9
66	Viral Infections in Patients with Hematological Malignancies. , 2018, , 1079-1127.		1
67	The microbiome: more than a gut reaction. Blood, 2018, 131, 2874-2875.	0.6	3
68	Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features. Case Reports in Hematology, 2018, 2018, 1-5.	0.3	9
69	PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis. Journal of Clinical Microbiology, 2018, 56, .	1.8	77
70	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2018, 5, e563-e598.	2.2	97
71	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. Blood, 2018, 132, 1015-1015.	0.6	2
72	Microbiota Phylogenetic Analysis Revealed Decreased Abundance of Faecalibacterium Prausnitzii, an Anti-Inflammatory Commensal Bacterium, in Patients with Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 2119-2119.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Clinical factors influencing engraftment in patients with non-Hodgkin lymphoma following autologous stem cell transplant.. Journal of Clinical Oncology, 2018, 36, e19504-e19504.	0.8	0
74	Platelet count and transfusion dependence as prognostic factors of engraftment in autologous stem cell transplantation.. Journal of Clinical Oncology, 2018, 36, e20001-e20001.	0.8	0
75	iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).. Journal of Clinical Oncology, 2018, 36, 7024-7024.	0.8	0
76	Abstract 3253: Droplet digital PCR is a sensitive method for detecting refractory acute myeloid leukemia (AML) clones in peripheral blood and saliva. , 2018, , .		1
77	Weighty Choices: Selecting Optimal G-CSF Doses for Stem Cell Mobilization to Optimize Yield. Blood, 2018, 132, 193-193.	0.6	0
78	Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Molecular Therapy - Methods and Clinical Development, 2017, 4, 178-191.	1.8	62
79	Guarded promise for adenovirus therapy. Blood, 2017, 129, 1899-1900.	0.6	1
80	A Prospective Biopsychosocial Investigation Into Head and Neck Cancer Caregiving. Biological Research for Nursing, 2017, 19, 87-96.	1.0	4
81	Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity. Respiratory Medicine Case Reports, 2017, 21, 154-157.	0.2	10
82	Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer Journal, 2017, 7, 634.	2.8	21
83	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 870-881.	2.0	38
84	Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). Biology of Blood and Marrow Transplantation, 2017, 23, 161-164.	2.0	10
85	Paroxysmal Nocturnal Hemoglobinuria in Pregnancy: A Dilemma in Treatment and Thromboprophylaxis. Case Reports in Hematology, 2017, 2017, 1-3.	0.3	5
86	Recent advances in hematopoietic stem cell transplantation. F1000Research, 2017, 6, 870.	0.8	31
87	Effect of melphalan 140Âmg/m ² vs 200Âmg/m ² on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantationâ€”a single center experience. Clinical Transplantation, 2016, 30, 894-900.	0.8	14
88	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 63, e1-e60.	2.9	1,861
89	Low Frequency of Second Autologous STEM CELL Transplantation (ASCT) for Multiple Myeloma (MM) Patients (PTS) Aged 65 YEARS and ABOVE in the Modern Era. Biology of Blood and Marrow Transplantation, 2016, 22, S228.	2.0	0
90	Burden, quality of life, and social support in caregivers of patients undergoing radiotherapy for head and neck cancer: A pilot study. Chronic Illness, 2016, 12, 236-245.	0.6	42

#	ARTICLE	IF	CITATIONS
91	Plerixafor Used in a "Just in Time" Fashion Allows Timely Autologous Hematopoietic Cell Transplant (HCT) in Patients Who Are at High Risk for Inadequate Apheresis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S126.	2.0	0
92	Associations Among Health-Promoting Lifestyle Behaviors, Perceived Stress, and Inflammatory Responses of Individuals with Chronic Graft-Versus-Host Disease (cGVHD) Following Allogeneic Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S470-S471.	2.0	2
93	Impact of early CMV reactivation in cord blood stem cell recipients in the current era. <i>Bone Marrow Transplantation</i> , 2016, 51, 1113-1120.	1.3	36
94	Association of mannose-binding lectin levels and invasive fungal disease in hematologic malignancy patients receiving myelosuppressive chemotherapy or allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 1228-1232.	1.3	6
95	A new model to predict remission status in AML patients based on day 14 bone marrow biopsy. <i>Leukemia Research</i> , 2016, 46, 69-73.	0.4	12
96	Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2234-2240.	1.3	10
97	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016, 127, 2427-2438.	0.6	403
98	A sniff to chase ill humors away. <i>Blood</i> , 2016, 128, 889-890.	0.6	0
99	Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2256-2263.	2.0	20
100	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
101	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, 433-442.	2.9	295
102	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1915-1925.	2.0	130
103	Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT) Tj ETQq1 1 0.784314rgBT / 0	2.0	57
104	Resolution of Severe Ulcerative Colitis after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S119.	2.0	0
105	Community Acquired Respiratory Viral Infections (CARV) in Patients with Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S178.	2.0	0
106	Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1108-1116.	2.0	26
107	Associations Among Inflammation, Perceived Stress, and Lifestyle Behaviors of Individuals with Chronic Graft-Versus-Host Disease (cGVHD) Following Allogeneic Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S187.	2.0	0
108	Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells. <i>Cytotherapy</i> , 2016, 18, 465-480.	0.3	21

#	ARTICLE	IF	CITATIONS
109	The incidence, mortality and timing of <i>Pneumocystis jirovecii</i> pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 573-580.	1.3	68
110	Risk factors and impact of non- <i>Aspergillus</i> mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 277-282.	1.3	29
111	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 359-370.	2.0	127
112	Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies. <i>Blood</i> , 2016, 128, 1187-1187.	0.6	13
113	Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS. <i>Blood</i> , 2016, 128, 594-594.	0.6	5
114	Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016, 128, 683-683.	0.6	3
115	Patient and provider preferences: Treatment summary and survivorship care plans after hematopoietic cell transplant.. <i>Journal of Clinical Oncology</i> , 2016, 34, 63-63.	0.8	3
116	Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5832-5832.	0.6	0
117	Patient and Provider Preferences for Survivorship Care Plans for Allogeneic Hematopoietic Cell Transplantation (HCT) Survivors: A Qualitative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S174-S175.	2.0	0
118	Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians. <i>Transfusion</i> , 2015, 55, 1766-1771.	0.8	5
119	Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens. <i>PLoS ONE</i> , 2015, 10, e0143165.	1.1	20
120	Valganciclovir for the Prevention of Complications of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation. <i>Annals of Internal Medicine</i> , 2015, 162, 1-10.	2.0	322
121	Relationships among symptoms, psychosocial factors, and health-related quality of life in hematopoietic stem cell transplant survivors. <i>Supportive Care in Cancer</i> , 2015, 23, 797-807.	1.0	49
122	Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. <i>Blood</i> , 2015, 125, 3778-3788.	0.6	29
123	Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. <i>Leukemia Research Reports</i> , 2015, 4, 24-27.	0.2	17
124	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1815-1822.	2.0	13
125	Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 688-695.	2.0	16
126	More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S49-S50.	2.0	4

#	ARTICLE	IF	CITATIONS
127	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104
128	<i>Aspergillus</i> Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. <i>Clinical Infectious Diseases</i> , 2015, 61, 1293-1303.	2.9	157
129	Combination Antifungal Therapy for Invasive Aspergillosis. <i>Annals of Internal Medicine</i> , 2015, 162, 81-89.	2.0	376
130	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). <i>Medical Mycology</i> , 2015, 53, 440-446.	0.3	79
131	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
132	Secondary solid cancer screening following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1013-1023.	1.3	136
133	Poor Peripheral Blood Stem Cell Mobilization Correlates with Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S129.	2.0	0
134	Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1870-1882.	2.0	54
135	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838.	2.0	12
136	Race and Ethnicity Influences Collection of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 165-171.	2.0	26
137	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. <i>Bone Marrow Transplantation</i> , 2015, 50, 197-203.	1.3	37
138	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 2020-2028.	3.2	98
139	The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS. <i>Blood</i> , 2015, 126, 4936-4936.	0.6	4
140	Effect of Melphalan 140 Mg/m ² Versus 200 Mg/m ² on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1988-1988.	0.6	0
141	A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy. <i>Blood</i> , 2015, 126, 3852-3852.	0.6	0
142	Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes. <i>Blood</i> , 2015, 126, 3221-3221.	0.6	0
143	Clinical guide to fertility preservation in hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2014, 49, 477-484.	1.3	96
144	Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant—A Prospective Phase II Study. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S16835.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Aztreonam for febrile neutropenia in patients with beta-lactam allergy. <i>Transplant Infectious Disease</i> , 2014, 16, 145-152.	0.7	6
146	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 858-864.	2.0	78
147	Long-Term Stability at 20°C of Aspergillus Galactomannan in Serum and Bronchoalveolar Lavage Specimens. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2108-2111.	1.8	15
148	Reduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2199-2201.	1.8	55
149	Elevated incidence of chronic myeloid leukaemia in immunosuppressed solid organ transplant recipients. <i>British Journal of Haematology</i> , 2014, 166, 619-621.	1.2	6
150	Update on Epidemiology of and Preventive Strategies for Invasive Fungal Infections in Cancer Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, S352-S355.	2.9	54
151	Reply to "Insufficient Demonstration of Long-Term Stability of Aspergillus Galactomannan". <i>Journal of Clinical Microbiology</i> , 2014, 52, 4119-4119.	1.8	3
152	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
153	Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1262-1273.	2.0	176
154	Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 600-616.	2.0	68
155	Health-related Quality of Life of Bone Marrow versus Peripheral Blood Stem Cell Donors: A Prespecified Subgroup Analysis from a Phase III RCT—BMTCTN Protocol 0201. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 118-127.	2.0	27
156	Monitoring of GRAFT Versus Leukemia Effect with CD34+ Specific DONOR Chimerism Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S276-S277.	2.0	0
157	Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1530-1536.	2.0	78
158	Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Blood</i> , 2014, 124, 206-206.	0.6	8
159	Severe Diffuse Alveolar Hemorrhage Associated with Bortezomib Administration in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 5761-5761.	0.6	5
160	Advances in the Management of Viral Infections. <i>Cancer Treatment and Research</i> , 2014, 161, 157-180.	0.2	1
161	Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. <i>Blood</i> , 2014, 124, 209-209.	0.6	0
162	Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2013, 48, 1091-1097.	1.3	58

#	ARTICLE	IF	CITATIONS
163	Continuous Infusion Cyclophosphamide and Low-Dose Total Body Irradiation Is a Safe and Effective Conditioning Regimen for Autologous Transplant in Multiple Myeloma. <i>Transplantation Proceedings</i> , 2013, 45, 3361-3365.	0.3	10
164	Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. <i>Bone Marrow Transplantation</i> , 2013, 48, 10-18.	1.3	43
165	Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S169.	2.0	4
166	Development and Evaluation of a Calibrator Material for Nucleic Acid-Based Assays for Diagnosing Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2403-2405.	1.8	22
167	Continuous Infusion Cyclophosphamide and Low Dose Total Body Irradiation (CICy/IdTBI) As a Conditioning Regimen for Tandem Autologous Transplant in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S181.	2.0	0
168	Association of Mannose Binding Lectin (MBL) Levels and Invasive Fungal Disease (IFD) in Hematologic Malignancy Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) or Receiving Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S226-S227.	2.0	0
169	Viral Infections in Patients with Hematological Malignancies. , 2013, , 1193-1239.		0
170	Autologous Umbilical Cord Blood Infusion followed by Oral Docosahexaenoic Acid and Vitamin D Supplementation for C-Peptide Preservation in Children with Type 1 Diabetes. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1126-1129.	2.0	47
171	Umbilical cord blood graft enhancement strategies: has the time come to move these into the clinic?. <i>Bone Marrow Transplantation</i> , 2013, 48, 884-889.	1.3	36
172	Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1518-1527.	0.5	13
173	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013, 121, 197-206.	0.6	123
174	Diagnostic Strategies for Invasive Fungal Infections in Patients With Hematologic Malignancies and Hematopoietic Stem Cell Transplant Recipients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 941-949.	2.3	9
175	A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013, 122, 1463-1463.	0.6	10
176	Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Blood</i> , 2013, 122, 699-699.	0.6	1
177	Vitamin D Effect On Umbilical Cord Blood Characteristics: A Comparison Between African Americans and Caucasians. <i>Blood</i> , 2013, 122, 693-693.	0.6	0
178	Effect Of Cumulative Adverse Clinical Risk Factors On Patients With Multiple Myeloma Undergoing First G-CSF Apheresis. <i>Blood</i> , 2013, 122, 4520-4520.	0.6	0
179	Influence Of Race and Ethnicity On The Collection Of G-CSF Mobilized Peripheral Blood Stem Cells From Unrelated Donors, a Center For International Blood and Marrow Transplant Research Analysis. <i>Blood</i> , 2013, 122, 3273-3273.	0.6	0
180	Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows. <i>Blood</i> , 2013, 122, 1412-1412.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. <i>Current Opinion in Hematology</i> , 2012, 19, 21-26.	1.2	24
182	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. <i>New England Journal of Medicine</i> , 2012, 367, 1487-1496.	13.9	762
183	How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. <i>Blood</i> , 2012, 120, 1791-1800.	0.6	55
184	Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies. <i>Expert Review of Hematology</i> , 2012, 5, 661-669.	1.0	21
185	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2012, 5, 1-30.	0.6	71
186	Quality of Life, Social Challenges, and Psychosocial Support for Long-Term Survivors After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Seminars in Hematology</i> , 2012, 49, 104-109.	1.8	41
187	Comparative Outcomes of Donor Graft CD34 ⁺ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3194-3201.	0.8	143
188	Serum IgG Responses against Aspergillus Proteins before Hematopoietic Stem Cell Transplantation or Chemotherapy Identify Patients Who Develop Invasive Aspergillosis. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1927-1934.	2.0	16
189	Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1851-1858.	2.0	28
190	Relationship of Race/Ethnicity and Survival after Single Umbilical Cord Blood Transplantation for Adults and Children with Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 903-912.	2.0	43
191	Impact of Chronic GVHD on Late Relapse, Treatment Related Mortality and Survival After Allogeneic Hematopoietic Cell Transplantation for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S209-S210.	2.0	0
192	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 348-371.	2.0	324
193	Armed Killers Face Off against Cytomegalovirus. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 977-978.	2.0	2
194	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1150-1163.	2.0	506
195	Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation?. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 487-491.	0.7	11
196	African American adult apheresis donors respond to granulocyte colony-stimulating factor with neutrophil and progenitor cell yields comparable to those of Caucasian and Hispanic donors. <i>Transfusion</i> , 2012, 52, 166-172.	0.8	9
197	Characteristics of thawed autologous umbilical cord blood. <i>Transfusion</i> , 2012, 52, 2234-2242.	0.8	16
198	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012, 120, 739-739.	0.6	19

#	ARTICLE	IF	CITATIONS
199	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 109-133.	0.7	207
200	Abstract 4618: Response post first autologous stem cell transplantation (ASCT) for multiple myeloma identify patients who may benefit from tandem transplants: A single center prospective phase II study. , 2012, , .		0
201	Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update. <i>Blood</i> , 2012, 120, 2023-2023.	0.6	0
202	Continuous Infusion Cyclophosphamide and Low Dose Total Body Irradiation (CICy/IdTBI) As a Conditioning Regimen for Tandem Autologous Transplant in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4524-4524.	0.6	2
203	Peripheral Blood CD34+ Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.. <i>Blood</i> , 2012, 120, 3074-3074.	0.6	0
204	A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012, 120, 4335-4335.	0.6	0
205	Higher Than Expected Incidence of Chronic Myeloid Leukemia in Solid Organ Transplant Recipients.. <i>Blood</i> , 2012, 120, 2799-2799.	0.6	0
206	Comparison of lasting life changes after cancer and BMT: perspectives of long-term survivors and spouses. <i>Psycho-Oncology</i> , 2011, 20, 926-934.	1.0	25
207	Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2011, 52, e56-e93.	2.9	2,434
208	Hematopoietic Stem Cell Transplantation: An Overview of Infection Risks and Epidemiology. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 101-116.	0.9	59
209	Pregnancy after Hematopoietic Cell Transplantation: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 157-166.	2.0	91
210	Generic Immunosuppressants in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 285-290.	2.0	12
211	Galactomannan Testing in Bronchoalveolar Lavage Fluid Facilitates the Diagnosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies and Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1043-1050.	2.0	69
212	Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1375-1382.	2.0	188
213	Malignancies after Hematopoietic Cell Transplantation for Primary Immune Deficiencies: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1783-1789.	2.0	28
214	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011, 117, 6714-6720.	0.6	128
215	Invasive Non- <i>Aspergillus</i> Mold Infections in Transplant Recipients, United States, 2001-2006. <i>Emerging Infectious Diseases</i> , 2011, 17, 1855-1864.	2.0	250
216	Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. <i>Blood</i> , 2011, 117, 316-322.	0.6	182

#	ARTICLE	IF	CITATIONS
217	Pandemic influenza: was the concern warranted?. Blood, 2011, 117, 5012-5013.	0.6	0
218	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood, 2011, 118, 282-288.	0.6	549
219	Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood, 2011, 118, 4472-4479.	0.6	52
220	Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide. Diabetes Care, 2011, 34, 2567-2569.	4.3	61
221	Assessing Responses to Treatment of Opportunistic Mycoses and Salvage Strategies. Current Infectious Disease Reports, 2011, 13, 492-503.	1.3	3
222	Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2011, 29, 2230-2239.	0.8	530
223	Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2011, 52, 427-431.	2.9	635
224	Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. Blood, 2011, 118, 1-1.	0.6	24
225	Controversies in Empiric Therapy of Febrile Neutropenia. , 2011, , 105-111.		0
226	Reinduction Chemotherapy for AML: Comparison Between CECA, High Dose Cytarabine and CLAG-M. Blood, 2011, 118, 4301-4301.	0.6	1
227	Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2011, 118, 4462-4462.	0.6	0
228	CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia. Blood, 2011, 118, 4299-4299.	0.6	0
229	Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B. Medicine (United States), 2010, 89, 236-244.	0.4	81
230	Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010, 116, 5111-5118.	0.6	419
231	Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2010, 45, 31-37.	1.3	2
232	Galactomannan Testing In Bronchoalveolar Lavage Fluid Facilitates The Diagnosis Of Invasive Pulmonary Aspergillosis And Is Not Influenced By Short-course Antifungal Therapy. , 2010, , .		0
233	Combination of IFN- γ /Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients after Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study. Clinical Medicine Insights: Oncology, 2010, 4, CMO.S6161.	0.6	5
234	Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis. Clinical Infectious Diseases, 2010, 50, 1559-1567.	2.9	269

#	ARTICLE	IF	CITATIONS
235	Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. <i>Clinical Infectious Diseases</i> , 2010, 50, 1091-1100.	2.9	1,194
236	Serological Profiling of a <i>Candida albicans</i> Protein Microarray Reveals Permanent Host-Pathogen Interplay and Stage-Specific Responses during Candidemia. <i>PLoS Pathogens</i> , 2010, 6, e1000827.	2.1	66
237	Hematopoietic Stem Cell Transplantation: An Overview of Infection Risks and Epidemiology. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 257-272.	1.9	142
238	<i>Aspergillus</i> DNA contamination in blood collection tubes. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 392-394.	0.8	54
239	Antifungal Management. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 441-442.	2.0	3
240	The National Marrow Donor Program's Symposium on Patient Advocacy in Cellular Transplantation Therapy: Addressing Barriers to Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 147-156.	2.0	15
241	The Preventive Health Behaviors of Long-Term Survivors of Cancer and Hematopoietic Stem Cell Transplantation Compared with Matched Controls. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 207-214.	2.0	63
242	Second Solid Cancers After Allogeneic Hematopoietic-Cell Transplantation Using Busulfan-Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S176-S177.	2.0	0
243	African American Adult Donors Respond To G-CSF With Progenitor Cell Yields Comparable To Caucasian And Hispanic Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S214-S215.	2.0	0
244	Spiritual Absence and 1-Year Mortality after Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1171-1179.	2.0	48
245	Factors Associated with Self-Reported Physical and Mental Health after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1682-1692.	2.0	41
246	Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation. <i>Blood</i> , 2010, 116, 224-224.	0.6	2
247	Amphotericin B (AMB)., 2010, , 1693-1727.		1
248	Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Scores Correlates with Increased Readmissions and Days In Hospital In Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2010, 116, 4748-4748.	0.6	0
249	Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis. <i>Blood</i> , 2010, 116, 898-898.	0.6	0
250	Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2010, 116, 211-211.	0.6	0
251	Health-Related Quality-of-Life Among Adult Matched Unrelated Stem Cell Donors: A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Randomized Trial of Marrow Versus PBSC Donation. <i>Blood</i> , 2010, 116, 366-366.	0.6	8
252	Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 40-6.	0.3	23

#	ARTICLE	IF	CITATIONS
253	Current Approaches in Antifungal Prophylaxis in High Risk Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients. <i>Mycopathologia</i> , 2009, 168, 299-311.	1.3	32
254	Fungal infection prevention after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2009, 44, 483-487.	1.3	51
255	<i>Strongyloides stercoralis</i> hyperinfection in hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2009, 11, 143-148.	0.7	53
256	Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 144-154.	2.0	41
257	Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2041-2046.	4.3	87
258	Methodology for Updating Published Evidence-Based Reviews Evaluating the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: A Policy Statement by the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 761-762.	2.0	9
259	Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1143-1238.	2.0	1,505
260	Solid cancers after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2009, 113, 1175-1183.	0.6	427
261	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 113, 3110-3118.	0.6	147
262	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	0.6	143
263	Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i> , 2009, 114, 511-517.	0.6	217
264	Stem Cell Transplantation. , 2009, , 211-231.		0
265	Clinical Manifestations of Invasive Pulmonary Aspergillosis. , 2009, , 381-389.		0
266	Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders.. <i>Blood</i> , 2009, 114, 520-520.	0.6	0
267	Combination antifungal therapy: From bench to bedside. <i>Current Infectious Disease Reports</i> , 2008, 10, 466-472.	1.3	15
268	Combination antifungal therapy: From bench to bedside. <i>Current Fungal Infection Reports</i> , 2008, 2, 43-48.	0.9	6
269	Changes in causes of death over time after treatment for invasive aspergillosis. <i>Cancer</i> , 2008, 112, 2309-2312.	2.0	77
270	Bone marrow sinusoidal endothelial cells undergo nonapoptotic cell death and are replaced by proliferating sinusoidal cells in situ to maintain the vascular niche following lethal irradiation. <i>Experimental Hematology</i> , 2008, 36, 1143-1156.e3.	0.2	59

#	ARTICLE	IF	CITATIONS
271	189: Non-Myeloablative Allogeneic Stem Cell Transplantation to Treat High Risk Heavily Pretreated Multiple. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 69-70.	2.0	0
272	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	2.9	4,375
273	Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study. <i>Leukemia and Lymphoma</i> , 2008, 49, 306-314.	0.6	26
274	Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2008, 46, 327-360.	2.9	2,432
275	Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA). <i>Clinical Infectious Diseases</i> , 2008, 46, T1-T36.	2.9	4
276	Performance Characteristics of the Platelia <i>Aspergillus</i> Enzyme Immunoassay for Detection of <i>Aspergillus</i> Galactomannan Antigen in Bronchoalveolar Lavage Fluid. <i>Vaccine Journal</i> , 2008, 15, 1760-1763.	3.2	100
277	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	2.9	368
278	Immunoglobulin G Responses to a Panel of <i>Candida albicans</i> Antigens as Accurate and Early Markers for the Presence of Systemic Candidiasis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 1647-1654.	1.8	58
279	Editorial Commentary: Learning from Our Failures: The Antifungal Treatment Conundrum. <i>Clinical Infectious Diseases</i> , 2008, 46, 1434-1435.	2.9	12
280	Transplanted Human Cord Blood Cells Generate Amylase-Producing Pancreatic Acinar Cells in Engrafted Mice. <i>Pancreas</i> , 2008, 36, e30-e35.	0.5	8
281	Influenza: Preparedness for an Inevitable "Emergency" for Oncology and BMT Units. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 215-222.	2.3	12
282	BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD). <i>Blood</i> , 2008, 112, 55-55.	0.6	3
283	Effect of the Absolute Lymphocyte Count on Induction Chemotherapy Outcomes in Adult Patients with Acute Leukemia. <i>Blood</i> , 2008, 112, 4853-4853.	0.6	2
284	Pathogenesis of <i>Aspergillus fumigatus</i> and the Kinetics of Galactomannan in an In Vitro Model of Early Invasive Pulmonary Aspergillosis: Implications for Antifungal Therapy. <i>Journal of Infectious Diseases</i> , 2007, 195, 455-466.	1.9	121
285	Use of Bronchoalveolar Lavage To Detect Galactomannan for Diagnosis of Pulmonary Aspergillosis among Nonimmunocompromised Hosts. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2787-2792.	1.8	84
286	Prevention and Early Treatment of Invasive Fungal Infection in Patients with Cancer and Neutropenia and in Stem Cell Transplant Recipients in the Era of Newer Broad-Spectrum Antifungal Agents and Diagnostic Adjuncts. <i>Clinical Infectious Diseases</i> , 2007, 44, 402-409.	2.9	166
287	Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 637-643.	0.5	30
288	Bronchoalveolar Lavage Galactomannan in Diagnosis of Invasive Pulmonary Aspergillosis among Solid-Organ Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1759-1765.	1.8	198

#	ARTICLE	IF	CITATIONS
289	Late Effects of Cancer and Hematopoietic Stem-Cell Transplantation on Spouses or Partners Compared With Survivors and Survivor-Matched Controls. <i>Journal of Clinical Oncology</i> , 2007, 25, 1403-1411.	0.8	176
290	Reply to Verweij et al. <i>Clinical Infectious Diseases</i> , 2007, 44, 1667-1668.	2.9	5
291	Spatial Distribution of Blood Vessels and CD34+ Hematopoietic Stem and Progenitor Cells Within the Marrow Cavities of Human Cancellous Bone. <i>Journal of Nuclear Medicine</i> , 2007, 48, 645-654.	2.8	39
292	Facing the Next Pandemic: Ready or Not. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 107-109.	2.0	8
293	Radiation Emergencies: Evaluation, Management, and Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 103-106.	2.0	7
294	Umbilical Cord Blood Produces Small Megakaryocytes After Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 145-150.	2.0	24
295	Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1461-1468.	2.0	174
296	Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign. <i>Clinical Infectious Diseases</i> , 2007, 44, 373-379.	2.9	524
297	New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 99-107.	0.7	20
298	Unrelated cord blood transplantation in children with sickle cell disease: Review of four-center experience. <i>Pediatric Transplantation</i> , 2007, 11, 641-644.	0.5	72
299	Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2007, 9, 182-188.	0.7	25
300	Sites and kinetics of donor thrombopoiesis following transplantation of whole bone marrow and progenitor subsets. <i>Experimental Hematology</i> , 2007, 35, 1567-1579.	0.2	2
301	The Role of the Donor in the Repair of the Marrow Vascular Niche Following Hematopoietic Stem Cell Transplant. <i>Stem Cells</i> , 2007, 25, 2945-2955.	1.4	60
302	Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients.. <i>Blood</i> , 2007, 110, 163-163.	0.6	60
303	Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.. <i>Blood</i> , 2007, 110, 3049-3049.	0.6	1
304	Bone Marrow Sinusoidal Endothelium Undergoes DNA Damage and Repair Following Lethal Irradiation.. <i>Blood</i> , 2007, 110, 4866-4866.	0.6	0
305	Wilm's Tumor 1 Gene Expression Is a Useful Marker for Minimal Residual Disease in Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 4240-4240.	0.6	0
306	Recommended Screening and Preventive Practices for Long-term Survivors after Hematopoietic Cell Transplantation: Joint Recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 138-151.	2.0	238

#	ARTICLE	IF	CITATIONS
307	Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 325-334.	2.0	69
308	Preparing for the Unthinkable: Emergency Preparedness for the Hematopoietic Cell Transplant Program. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1229-1238.	2.0	8
309	Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic stem-cell transplant recipients?. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 371-379.	1.3	6
310	Factors associated with parameters of engraftment potential of umbilical cord blood. <i>Transfusion</i> , 2006, 46, 1803-1812.	0.8	49
311	New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. <i>Blood Reviews</i> , 2006, 20, 267-287.	2.8	30
312	Posaconazole as Salvage Therapy for Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 126-133.	1.4	523
313	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. <i>Clinical Infectious Diseases</i> , 2006, 43, 1031-1039.	2.9	3
314	Invasive Fungal Pathogens: Current Epidemiological Trends. <i>Clinical Infectious Diseases</i> , 2006, 43, S3-S14.	2.9	352
315	Flow Cytometric Disease Monitoring in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Retrospective Study.. <i>Blood</i> , 2006, 108, 5014-5014.	0.6	0
316	The changing face of invasive fungal infections in hematopoietic cell transplant recipients. <i>Current Opinion in Oncology</i> , 2005, 17, 89-92.	1.1	51
317	Study of Renal Safety in Amphotericin B Lipid Complex-Treated Patients. <i>Clinical Infectious Diseases</i> , 2005, 40, S414-S421.	2.9	67
318	Hepatotoxicity Associated with Antifungal Therapy after Bone Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 2005, 41, 308-310.	2.9	17
319	Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome. <i>Clinical Infectious Diseases</i> , 2005, 41, 1448-1452.	2.9	106
320	Multicenter Clinical Evaluation of the (1->3) β -D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans. <i>Clinical Infectious Diseases</i> , 2005, 41, 654-659.	2.9	640
321	Long-Term Health-Related Quality of Life, Growth, and Spiritual Well-Being After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2005, 23, 599-608.	0.8	284
322	Tandem autografts for multiple myeloma patients using two different conditioning regimens: An interim analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 65-66.	2.0	74
323	An Assay for Human Hematopoietic Stem Cells Based on Transplantation into Nonobese Diabetic Recombination Activating Gene-Null Perforin-Null Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 487-494.	2.0	6
324	Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 698-705.	2.0	17

#	ARTICLE	IF	CITATIONS
325	The Evolution of the Evidence-Based Review: Evaluating the Science Enhances the Art of Medicine—Statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 819-822.	2.0	19
326	Interleukin 12 Is Associated with Reduced Relapse without Increased Incidence of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 1014-1021.	2.0	47
327	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956.	2.0	3,213
328	Caspofungin versus amphotericin B for candidemia: A pharmaco-economic analysis. <i>Clinical Therapeutics</i> , 2005, 27, 960-969.	1.1	27
329	Developmental Differences in Megakaryocyte Maturation Are Determined by the Microenvironment. <i>Stem Cells</i> , 2005, 23, 1400-1408.	1.4	41
330	Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience. <i>Blood</i> , 2005, 106, 2044-2044.	0.6	3
331	Donor-Derived Hematopoietic Stem Cells Repair the Bone Marrow Sinusoids Following Bone Marrow Transplant. <i>Blood</i> , 2005, 106, 1714-1714.	0.6	0
332	Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2005, 3, 773-7.	0.3	11
333	Reply to Powers. <i>Clinical Infectious Diseases</i> , 2004, 39, 1739-1739.	2.9	1
334	The Design of Clinical Trials That Evaluate Antifungal Prophylaxis and Combination Therapy: Introduction and Overview. <i>Clinical Infectious Diseases</i> , 2004, 39, S165-S169.	2.9	8
335	Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. <i>Clinical Infectious Diseases</i> , 2004, 39, S38-S43.	2.9	66
336	Supportive Care. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 372-389.	0.9	12
337	Design Issues in a Prospective Randomized Double-Blinded Trial of Prophylaxis with Fluconazole versus Voriconazole after Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2004, 39, S176-S180.	2.9	19
338	Granulocytic Sarcoma (Chloroma) of the Breast: A Diagnostic Dilemma and Review of the Literature. <i>Breast Journal</i> , 2004, 10, 48-53.	0.4	37
339	Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. <i>Bone Marrow Transplantation</i> , 2004, 34, 405-411.	1.3	38
340	A phase III, randomized, double-blind, placebo-controlled, study of isegagan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. <i>Leukemia Research</i> , 2004, 28, 559-565.	0.4	65
341	Thriving after hematopoietic stem cell transplant: a focus on positive changes in quality of life. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 111-123.	0.7	8
342	A new era of antifungal therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 73-90.	2.0	100

#	ARTICLE	IF	CITATIONS
343	The gift of life comes with a price: the impact of hematopoietic cell transplant on the long-term quality of life of survivors and their spouses. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 7-8.	2.0	5
344	Filgrastim (G-CSF) is beneficial after autologous peripheral blood grafts with high CD34+ cell content. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 63.	2.0	0
345	Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 614-623.	2.0	32
346	Clinical consequences of oral mucositis. <i>Seminars in Oncology Nursing</i> , 2004, 20, 16-21.	0.7	51
347	Bone marrow transdifferentiation in brain after transplantation: a retrospective study. <i>Lancet</i> , The, 2004, 363, 1432-1437.	6.3	298
348	Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. <i>Blood</i> , 2004, 104, 2194-2200.	0.6	84
349	Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. <i>Blood</i> , 2004, 103, 4330-4335.	0.6	107
350	High Levels of Interleukin-12 Are Associated with Reduced Incidence of Relapse and Death without Increasing Acute Graft-Versus-Host Disease (AGVHD) after Allogeneic Stem Cell Transplantation (SCT).. <i>Blood</i> , 2004, 104, 295-295.	0.6	0
351	NOD-Rag1nullPrf1null Mice Support Long-Term Engraftment of Human Hematopoietic Stem Cells.. <i>Blood</i> , 2004, 104, 1184-1184.	0.6	0
352	Incorporation of Bone Marrow Derived Cells in Colonic Adenoma.. <i>Blood</i> , 2004, 104, 674-674.	0.6	0
353	Hospital Resource Utilization in Acute Invasive Aspergillosis (AIA) Patients (Pts) Treated with Voriconazole (VOR) or Amphotericin B (CAB).. <i>Blood</i> , 2004, 104, 88-88.	0.6	1
354	Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. <i>Cancer</i> , 2003, 98, 406-412.	2.0	51
355	Access to stem cell transplantation: Do women fare as well as men?. <i>American Journal of Hematology</i> , 2003, 72, 99-102.	2.0	16
356	Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2003, 73, 169-175.	2.0	24
357	Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. <i>Bone Marrow Transplantation</i> , 2003, 32, 1135-1143.	1.3	70
358	Human cord blood long-term engrafting cells are CD34+ CD38 ⁺ . <i>Leukemia</i> , 2003, 17, 960-964.	3.3	50
359	Transplanted Human Cord Blood Cells Give Rise to Hepatocytes in Engrafted Mice. <i>Annals of the New York Academy of Sciences</i> , 2003, 996, 174-185.	1.8	126
360	Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 722-724.	2.0	16

#	ARTICLE	IF	CITATIONS
361	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 4-37.	2.0	85
362	Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 543-558.	2.0	396
363	Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2003, 44, 815-820.	0.6	91
364	A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial). <i>Leukemia and Lymphoma</i> , 2003, 44, 1165-1172.	0.6	60
365	Treatment of Refractory Acute Leukemia with Timed Sequential Chemotherapy Using Topotecan Followed by Etoposide+Mitoxantrone (T-EM) and Correlation with Topoisomerase II Levels. <i>Leukemia and Lymphoma</i> , 2002, 43, 989-999.	0.6	14
366	Increased Risk of Lethal Graft-Versus-Host Disease-like Syndrome after Transplantation into NOD/SCID Mice of Human Mobilized Peripheral Blood Stem Cells, As Compared to Bone Marrow or Cord Blood. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 277-292.	1.8	24
367	Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. <i>Journal of Medical Economics</i> , 2002, 5, 109-118.	1.0	9
368	Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever. <i>New England Journal of Medicine</i> , 2002, 346, 225-234.	13.9	940
369	Lipid Formulations of Amphotericins: Are You a Lumper or a Splitter?. <i>Clinical Infectious Diseases</i> , 2002, 35, 891-895.	2.9	54
370	A Double-blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2002, 35, 359-366.	2.9	308
371	Antifungal Chemoprophylaxis after Blood and Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 2002, 34, 1386-1390.	2.9	30
372	Stem Cell Transplantation: Supportive Care and Long-Term Complications. <i>Hematology American Society of Hematology Education Program</i> , 2002, 2002, 422-444.	0.9	68
373	Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. <i>Bone Marrow Transplantation</i> , 2002, 29, 15-19.	1.3	173
374	Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?. <i>Current Opinion in Infectious Diseases</i> , 2002, 15, 369-375.	1.3	16
375	Mismanaging the gift of life: noncompliance in the context of adult stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 29, 875-880.	1.3	17
376	GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation. <i>Cytotherapy</i> , 2002, 4, 531-538.	0.3	5
377	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. <i>New England Journal of Medicine</i> , 2002, 347, 408-415.	13.9	3,048
378	A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 569-576.	2.0	140

#	ARTICLE	IF	CITATIONS
379	Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 145-154.	2.0	177
380	Clinical research: The best or worst of times?. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 293-294.	2.0	0
381	Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVD), HVD-related mortality, and overall 100-day mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 493-500.	2.0	216
382	An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/ β 2-microglobulin null mice. <i>Experimental Hematology</i> , 2002, 30, 488-494.	0.2	48
383	Human stem-progenitor cells from neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood. <i>Experimental Hematology</i> , 2002, 30, 816-823.	0.2	88
384	Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. <i>Transfusion</i> , 2002, 42, 1279-1284.	0.8	44
385	Human CD34+Hematopoietic Stem/Progenitor Cells Express High Levels of FLIP and Are Resistant to Fas-Mediated Apoptosis. <i>Stem Cells</i> , 2002, 20, 174-182.	1.4	58
386	Caspofungin. <i>Drugs</i> , 2001, 61, 1130-1131.	4.9	0
387	Documenting the case for stem cell transplantation: The role of evidence-based reviews and implications for future research. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 306-307.	2.0	1
388	INFECTIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>Infectious Disease Clinics of North America</i> , 2001, 15, 483-520.	1.9	59
389	Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab. <i>Bone Marrow Transplantation</i> , 2001, 27, 329-332.	1.3	25
390	Gastroparesis following bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 59-62.	1.3	46
391	A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 187-196.	1.3	76
392	Evolution, Incidence, and Susceptibility of Bacterial Bloodstream Isolates from 519 Bone Marrow Transplant Patients. <i>Clinical Infectious Diseases</i> , 2001, 33, 947-953.	2.9	254
393	Monitoring vital signs in a bone marrow transplant unit: are they needed in the middle of the night?. <i>Bone Marrow Transplantation</i> , 2001, 27, 1197-1200.	1.3	8
394	Blood and Marrow Transplantation. , 2001, , 19-37.		8
395	A GRAFT ENGINEERING METHOD TO ALLOW BONE MARROW TRANSPLANTATION (BMT) FOR MORE HIGHLY MISMATCHED RECIPIENTS WITH LEUKEMIA: MULTIVARIATE ANALYSIS OF A PHASE I/II PROTOCOL.. <i>Transplantation</i> , 2000, 69, S294.	0.5	0
396	Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes. <i>Medicine (United States)</i> , 2000, 79, 250-260.	0.4	696

#	ARTICLE	IF	CITATIONS
397	Acquiescence to adjunctive experimental therapies may relate to psychological distress: pilot data from a bone marrow transplant center. <i>Bone Marrow Transplantation</i> , 2000, 25, 673-676.	1.3	6
398	Management of CMV Infections after Bone Marrow Transplantation: A Paradigm Shift. <i>Fetal and Pediatric Pathology</i> , 2000, 19, 205-220.	0.3	0
399	A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia. <i>Clinical Infectious Diseases</i> , 2000, 31, 1155-1163.	2.9	484
400	Status of high-dose chemotherapy for breast cancer: A review. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 476-495.	2.0	28
401	Evidence-Based Reviews and the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: An ASBMT Policy Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 523-525.	2.0	9
402	Characterization and Outcome of "Hard to Mobilize" Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2000, 39, 509-519.	0.6	79
403	Subcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents. <i>Medical Mycology</i> , 2000, 38, 169-175.	0.3	7
404	Treatment Results in Aplastic Anemia Trials Need To Be Analyzed Separately for Pediatric and Adult Populations. <i>Blood</i> , 1999, 94, 1833-1834.	0.6	6
405	Clinical Significance of Nephrotoxicity in Patients Treated with Amphotericin B for Suspected or Proven Aspergillosis. <i>Clinical Infectious Diseases</i> , 1999, 29, 1402-1407.	2.9	346
406	Opportunistic infections after blood and marrow transplantation. <i>Transplant Infectious Disease</i> , 1999, 1, 3-20.	0.7	62
407	High-Dose Chemotherapy with Autologous Stem Cell Rescue as a Treatment Modality for Breast Cancer. <i>Breast Journal</i> , 1999, 5, 308-318.	0.4	1
408	Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. <i>Bone Marrow Transplantation</i> , 1999, 23, 867-873.	1.3	16
409	Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 1053-1056.	1.3	54
410	Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 1323-1327.	1.3	26
411	Reintegration After Bone Marrow Transplantation. <i>Cancer Practice</i> , 1999, 7, 190-197.	0.8	109
412	Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation. <i>New England Journal of Medicine</i> , 1999, 341, 14-21.	13.9	666
413	Fungal infections after bone marrow transplant. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 55-68.	2.0	101
414	Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 94-97.	2.0	80

#	ARTICLE	IF	CITATIONS
415	Tacrolimus vs. cyclosporine immunosuppression: Results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 180-186.	2.0	32
416	Thalidomide in Children Undergoing Bone Marrow Transplantation: Series at a Single Institution and Review of the Literature. <i>Pediatrics</i> , 1999, 103, e44-e44.	1.0	29
417	Can 40 Seconds of Compassion Reduce Patient Anxiety?. <i>Journal of Clinical Oncology</i> , 1999, 17, 371-371.	0.8	445
418	Stem Cell Collection for Hematopoietic Transplantation: Stem Cell Sources, Mobilization Strategies, and Factors that Influence Yield. , 1999, , 341-356.		0
419	Adoptive Immunotherapy in Children Compared to Adults. <i>Pediatric Research</i> , 1999, 45, 150A-150A.	1.1	0
420	Tacrolimus pharmacokinetics in BMT patients. <i>Bone Marrow Transplantation</i> , 1998, 21, 23-28.	1.3	38
421	Successful salvage using mismatched umbilical cord blood transplant in an adult with recurrent acute myelogenous leukemia failing autologous peripheral blood progenitor cell transplant: a case history and review. <i>Bone Marrow Transplantation</i> , 1998, 21, 1197-1200.	1.3	9
422	Measurement of absolute concentration and viability of CD34+ cells in cord blood and cord blood products using fluorescent beads and cyanine nucleic acid dyes. <i>Cytometry</i> , 1998, 34, 121-127.	1.8	33
423	An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. <i>Supportive Care in Cancer</i> , 1998, 6, 511-517.	1.0	10
424	Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 1998, 4, 157-163.	2.0	31
425	Randomized, Double-blind Clinical Trial of Amphotericin B Colloidal Dispersion vs. Amphotericin B in the Empirical Treatment of Fever and Neutropenia. <i>Clinical Infectious Diseases</i> , 1998, 27, 296-302.	2.9	287
426	The Effect of Overnight Storage of Leukapheresis Stem Cell Products on Cell Viability, Recovery, and Cost. <i>Stem Cells and Development</i> , 1998, 7, 431-436.	1.0	19
427	Quality of life following bone marrow transplantation. <i>Current Opinion in Oncology</i> , 1998, 10, 108-111.	1.1	9
428	Efficacy of Low-Dose Dopamine in Preventing Amphotericin B Nephrotoxicity in Bone Marrow Transplant Patients and Leukemia Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 3103-3106.	1.4	22
429	Acute oral pain and mucositis in bone marrow transplant and leukemia patients: Data from a pilot study. <i>Cancer Nursing</i> , 1998, 21, 385-393.	0.7	59
430	Recent advances in the management of viral infections. , 1998, 96, 183-200.		0
431	The True Cost of Bone Marrow Transplantation. <i>American Journal of the Medical Sciences</i> , 1997, 314, 101-112.	0.4	1
432	Isolation and characterization of fluconazole- and amphotericin B-resistant <i>Candida albicans</i> from blood of two patients with leukemia. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 196-199.	1.4	201

#	ARTICLE	IF	CITATIONS
433	Successful engraftment after primary graft failure in aplastic anemia using G-CSF mobilized peripheral stem cell transfusions. <i>Bone Marrow Transplantation</i> , 1997, 19, 175-177.	1.3	13
434	Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. <i>Bone Marrow Transplantation</i> , 1997, 19, 343-347.	1.3	77
435	Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 1997, 20, 49-51.	1.3	10
436	Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation. <i>Bone Marrow Transplantation</i> , 1997, 20, 219-225.	1.3	15
437	The True Cost of Bone Marrow Transplantation. <i>American Journal of the Medical Sciences</i> , 1997, 314, 101-112.	0.4	15
438	HOST IMMUNOLOGIC AUGMENTATION FOR THE CONTROL OF INFECTION. <i>Infectious Disease Clinics of North America</i> , 1996, 10, 345-364.	1.9	2
439	Management of Viral Infections in Bone Marrow Transplant Recipients. <i>BioDrugs</i> , 1996, 6, 352-382.	0.7	0
440	Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1156-1164.	0.8	53
441	Coping with the physical and psychosocial sequelae of bone marrow transplantation among long-term survivors. <i>Journal of Behavioral Medicine</i> , 1996, 19, 163-184.	1.1	37
442	Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. <i>Hepatology</i> , 1996, 24, 588-591.	3.6	99
443	EVALUATION OF THE DRUG INTERACTION BETWEEN INTRAVENOUS HIGH-DOSE FLUCONAZOLE AND CYCLOSPORINE OR TACROLIMUS IN BONE MARROW TRANSPLANT PATIENTS. <i>Transplantation</i> , 1996, 61, 1268-1272.	0.5	81
444	Necrotizing cerebritis in an allogeneic bone marrow transplant recipient due to <i>Cladophialophora bantiana</i> . <i>Journal of Clinical Microbiology</i> , 1996, 34, 1330-1332.	1.8	27
445	Infectious complications of bone-marrow transplantation. <i>Current Opinion in Infectious Diseases</i> , 1995, 8, 241-246.	1.3	0
446	Sinusitis in the Bone Marrow Transplant Patient: Diagnosis and Management. <i>American Journal of Rhinology & Allergy</i> , 1995, 9, 31-36.	2.3	4
447	Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. <i>American Journal of Hematology</i> , 1995, 50, 167-172.	2.0	25
448	Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum d-arabinitol. <i>American Journal of Medicine</i> , 1995, 99, 164-172.	0.6	92
449	Importance of <i>Candida</i> Species Other than <i>C. albicans</i> as Pathogens in Oncology Patients. <i>Clinical Infectious Diseases</i> , 1995, 20, 115-125.	2.9	489
450	Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. <i>Journal of Clinical Microbiology</i> , 1995, 33, 1263-1266.	1.8	38

#	ARTICLE	IF	CITATIONS
451	Infections Due to Resistant <i>Candida</i> Species in Patients with Cancer Who Are Receiving Chemotherapy. <i>Clinical Infectious Diseases</i> , 1994, 19, S49-S53.	2.9	97
452	Viral infections in severely immunocompromised cancer patients. <i>Supportive Care in Cancer</i> , 1994, 2, 355-368.	1.0	21
453	Predictors of acute respiratory failure after bone marrow transplantation in children. <i>Critical Care Medicine</i> , 1994, 22, 1485-1491.	0.4	132
454	Changes in the Spectrum of Fungal Infections in Bone Marrow Transplant Patients. <i>Infectious Diseases in Clinical Practice</i> , 1994, 3, S83-S89.	0.1	5
455	Personal changes, dispositional optimism, and psychological adjustment to bone marrow transplantation. <i>Journal of Behavioral Medicine</i> , 1993, 16, 423-443.	1.1	184
456	Chromosome abnormalities in patients treated with 4-hydroperoxycyclophosphamide-purged autologous bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , 1993, 65, 135-140.	1.0	4
457	Association of <i>Torulopsis glabrata</i> infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 1847-1849.	1.4	344
458	Loss and Recovery Themes of Long-Term Survivors of Bone Marrow Transplants. <i>Journal of Psychosocial Oncology</i> , 1993, 10, 1-20.	0.6	51
459	The Use of Fluconazole Prophylaxis in Patients with Chemotherapy-Induced Neutropenia. <i>Leukemia and Lymphoma</i> , 1992, 8, 353-359.	0.6	12
460	Development of the Satisfaction with Life Domains Scale for Cancer. <i>Journal of Psychosocial Oncology</i> , 1992, 10, 75-90.	0.6	40
461	Thalidomide for the Treatment of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 1992, 326, 1055-1058.	13.9	411
462	Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits.. <i>Journal of Clinical Oncology</i> , 1992, 10, 779-789.	0.8	46
463	Optic Disc Edema after Bone Marrow Transplantation. <i>Ophthalmology</i> , 1991, 98, 1294-1301.	2.5	75
464	Increase in <i>Candida krusei</i> Infection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole. <i>New England Journal of Medicine</i> , 1991, 325, 1274-1277.	13.9	980
465	Health, Functional Status, and Employment of Adult Survivors of Bone Marrow Transplantation. <i>Annals of Internal Medicine</i> , 1991, 114, 113-118.	2.0	135
466	Oral mucositis after bone marrow transplantation. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1991, 72, 419-424.	0.6	32
467	Role retention and quality of life of bone marrow transplant survivors. <i>Social Science and Medicine</i> , 1991, 32, 697-704.	1.8	88
468	Orthotopic liver transplantation for graft-versus-host disease following bone marrow transplantation. <i>Gastroenterology</i> , 1990, 99, 536-538.	0.6	38

#	ARTICLE	IF	CITATIONS
469	Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1990, 8, 820-830.	0.8	92
470	Cytomegalovirus Infections in Bone Marrow Transplant Recipients Given Intensive Cytoreductive Therapy. Clinical Infectious Diseases, 1990, 12, S793-S804.	2.9	62
471	Herpesvirus and Enteric Viral Infections in Bone Marrow Transplantation Clinical Presentations, Pathogenesis, and Therapeutic Strategies. Cancer Investigation, 1990, 8, 509-521.	0.6	15
472	Coaggregation of oral Candida isolates with bacteria from bone marrow transplant recipients. Journal of Clinical Microbiology, 1990, 28, 2621-2626.	1.8	42
473	Longitudinal Changes in Pulmonary Function Following Bone Marrow Transplantation. Chest, 1989, 96, 301-306.	0.4	52
474	Cutaneous Graft-Versus-Host Reaction Lacks Evidence of Cutaneous Cytomegalovirus by the Immunoperoxidase Technique. Journal of Investigative Dermatology, 1989, 93, 92-95.	0.3	6
475	Interstitial Pneumonitis After Allogeneic Bone Marrow Transplantation NINE-YEAR EXPERIENCE AT A SINGLE INSTITUTION. Medicine (United States), 1988, 67, 175-186.	0.4	162
476	INTERSTITIAL PNEUMONITIS FOLLOWING AUTOLOGOUS BONE MARROW TRANSPLANTATION. Transplantation, 1988, 46, 61-65.	0.5	67
477	Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease.. Journal of Clinical Oncology, 1988, 6, 1558-1561.	0.8	36
478	Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole. American Journal of Medicine, 1987, 83, 1103-1110.	0.6	95
479	Differences between first and subsequent fevers during prolonged neutropenia. Cancer, 1987, 59, 844-849.	2.0	24
480	Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide. New England Journal of Medicine, 1986, 315, 141-147.	13.9	431
481	Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. Antimicrobial Agents and Chemotherapy, 1986, 30, 435-439.	1.4	36
482	Detection of Epstein-Barr virus DNA in mouthwashes by hybridization. Journal of Clinical Microbiology, 1985, 21, 353-356.	1.8	37
483	Genetic analysis of the susceptibility of mouse cytomegalovirus to acyclovir. Journal of Virology, 1985, 54, 104-113.	1.5	20
484	Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation. Antimicrobial Agents and Chemotherapy, 1983, 23, 593-597.	1.4	28
485	Acyclovir in mouse cytomegalovirus infections. American Journal of Medicine, 1982, 73, 118-124.	0.6	12
486	Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice. Infection and Immunity, 1982, 37, 833-836.	1.0	72

#	ARTICLE	IF	CITATIONS
487	Activity of trifluorothymidine against cytomegalovirus. <i>Antimicrobial Agents and Chemotherapy</i> , 1981, 20, 286-290.	1.4	30
488	Efficacy of acyclovir against mouse cytomegalovirus in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 1981, 20, 275-278.	1.4	16
489	Thymidine kinase not required for antiviral activity of acyclovir against mouse cytomegalovirus. <i>Journal of Virology</i> , 1981, 39, 889-893.	1.5	44
490	The Value of Fungal Surveillance Cultures as Predictors of Systemic Fungal Infections. <i>Journal of Infectious Diseases</i> , 1980, 142, 503-509.	1.9	229
491	<i>Candida tropicalis</i> : A Major Pathogen in Immunocompromised Patients. <i>Annals of Internal Medicine</i> , 1979, 91, 539.	2.0	299
492	Prevention and treatment of fungal infections in hematopoietic cell transplants. , 0, , 152-162.		0